SINERGIA grant for Frijlink
University of Groningen researcher Erik Frijlink (Pharmaceutical Technology and Biopharmacy), Fernando Stellacci (Polytechnical University of Lausanne), Caroline Tapparel Vu (University of Geneva) and Christian Münz (University of Zürich) have recently been awarded a Sinergia grant from the Swiss National Science Foundation for their project Novel virucidal drugs: from basic to in vivo studies. The project was granted 3.2M CHF (2.8M €), of which 800k CHF (700k €) will go to Frijlink’s group.
Viral diseases can best be prevented with vaccination, but recent outbreaks of emerging viruses and frequent influenza epidemics highlight that there is also an urgent need for effective drugs to treat these diseases. There are only a few antiviral drugs available and these are highly virus-specific and often not effective after mutation of the virus.
The Sinergia project will develop and test molecules that target a process present in all viruses and thus will be effective against a broad range of viruses instead of just one virus. For this a synergistic and multidisciplinary team has been assembled with expertise in material science, virology and drug formulation. If successful, this will be ground-breaking and pave the way to new generations of broad-spectrum antiviral drugs.
Last modified: | 26 September 2018 12.21 p.m. |
More news
-
21 May 2024
Results of 2024 University elections
The votes have been counted and the results of the University elections are in!
-
13 May 2024
Trapping molecules
In his laboratory, physicist Steven Hoekstra is building an experimental set-up made of two parts: one that produces barium fluoride molecules, and a second part that traps the molecules and brings them to an almost complete standstill so they can...